Skip to main content
eScholarship
Open Access Publications from the University of California

UC San Diego

UC San Diego Electronic Theses and Dissertations bannerUC San Diego

A Comprehensive Analysis of Patient Screen Failures in Personalized Cancer Therapy Trials: The UCSD-PREDICT Experience

Abstract

Background. Post-enrollment, pre-treatment screen failure is an under characterized source of inefficiency in oncology clinical trials. Interpretation is limited by inconsistent definitions, underreporting, and nonspecific reason labels. This study characterized screen failure mechanisms, identified patient-level and trial-level correlates, and developed an explanatory model of screen failure occurrence.Methods. This retrospective cohort study analyzed 4,060 enrollment events across 269 therapeutic oncology trials conducted from 2013 to 2021 at a single academic cancer center. Screen failure was defined as attrition between enrollment and participation at Cycle 1, Day 1. Failures were evaluated using hierarchical mechanism classification, univariable association analyses, and multilevel regression modelling with enrollment events nested within trials.Results. Screen failure occurred in 1,378 enrollment events (34.0%); 2,682 (66.0%) proceeded to participation. Most screen failures lacked recoverable mechanism attribution, because no reason was documented or documentation was insufficient for classification. When classifiable, failures reflected clinical deterioration, evidentiary and biologic confirmation burdens, treatment trajectory and protocol sequencing incompatibilities, operational and administrative gating, redirection of care, and end of life transition. Variation concentrated most clearly in tumor group, timing from diagnosis to enrollment, screening duration, and trial design and operating context, with risk highest closer to diagnosis. In multilevel modelling, screen failure propensity clustered within trials, and the implications of screening duration and domain-based eligibility requirements varied across trial contexts.Interpretation. Post-enrollment screen failure is best understood as a multi mechanism, context-dependent implementation outcome rather than a uniform endpoint of patient ineligibility or withdrawal. It arises through the interaction of protocol requirements, patients’ clinical and evidentiary trajectories during formal screening, and the operational conditions under which screening is conducted. Documentation opacity further limits the field’s ability to distinguish fixed design constraints from potentially modifiable screening failures. Conclusion. Reducing preventable screen failure will require more informative reason capture, reporting beyond pooled rates alone, and closer scrutiny of whether formal screening pathways can be completed reliably and on time. Particular attention should be paid to narrow time windows, multistep confirmation pathways, procedural dependencies, and prolonged screening trajectories.Limitations. This was a single-center observational study. Most screen failures lacked recoverable mechanism attribution, and domain-based eligibility counts may not fully capture screening burden.

Main Content

This item is under embargo until June 24, 2027.